X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BI-1206 is a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB. It is being evaluated in combination with rituximab in patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma.
Lead Product(s): BI-1206,Rituximab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which is investigated in combination with KEYTRUDA® (pembrolizumab) for the treatment of solid tumors, including melanoma.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Transgene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which encode both a Treg-depleting human recombinant anti-CTLA-4 antibody and the human GM-CSF cytokine.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Transgene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
BI-1206, a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB, in combination with rituximab in patients with relapsed/refractory Non-Hodgkin's Lymphoma (NHL).
Lead Product(s): BI1206,Rituximab
Therapeutic Area: Oncology Product Name: BI1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: CASI Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
BI-1607 is a novel, fully human FcγRIIB-blocking antibody with a novel mechanism-of-action, designed to enhance FcγR-dependent antitumor immunity and has potential of increasing therapeutic activity of other Fc-dependent therapeutic antibodies.
Lead Product(s): BI-1607,Trastuzumab
Therapeutic Area: Oncology Product Name: BI-1607
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Under the terms of the supply agreement, MSD will provide pembrolizumab to be used in combination with BT-001 in the ongoing Phase 1/2a clinical trial. BT-001 is being co-developed as part of a 50/50 collaboration between Transgene and BioInvent.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Transgene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2022
Details:
The initial data generated in Phase I part A demonstrated that BT-001 alone is well tolerated, with first signs of anti-tumor activity in a hard-to-treat population and confirmed the mechanism of action of BT‑001 as a single agent.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Transgene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
Target and antibody discovery will be performed using BioInvent’s proprietary n-CoDeR ® antibody library and patient-centric F.I.R.S.T™ screening platform, which together allow for parallel target and antibody discovery.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2022
Details:
BT-001, developed by BioInvent and Transgene, is a clinical phase oncolytic virus engineered to deliver an anti-CTLA-4 antibody and human GM-CSF in a tumor-specific vehicle (the VVcopTK-RR- virus backbone) for the treatment of solid tumors.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Transgene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
BI-1206 in combination with rituximab demonstrated an objective response rate (ORR) of 50%, with three complete responses and three partial responses seen in twelve patients evaluated for therapeutic benefit.
Lead Product(s): BI-1206,Rituximab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
